DNX-2401: an investigational drug for the treatment of recurrent glioblastoma.

DNX-2401: an investigational drug for the treatment of recurrent glioblastoma. Expert Opin Investig Drugs. 2019 Nov 14;: Authors: Philbrick B, Adamson DC Abstract INTRODUCTION: High grade gliomas (HGG) are extremely aggressive brain malignancies that are usually fatal. Despite maximal resection, chemotherapy and radiation, these tumors inevitably recur and present a poor median overall survival (mOS); hence there is a pressing need for improved treatments.Areas covered:This review assesses DNX-2401 as a treatment of recurrent HGG. Phase I data on efficacy, safety, and tolerability are examined while insights and perspectives on future directions are offered.Expert opinion:This phase I study assessed DNX-2401 in two groups; one group received a one-time intratumoral injection of DNX-2401 without tumor resection while the second group received an intratumoral injection of DNX-2401 followed by surgical resection 14 days later and a second injection of DNX-2401 into the resection cavity. In patients that did not receive resection, the mOS was 9.5 months across all cohorts while patients in the resection group had a mOS of 13 months which is a promising extension of survival compared to historical controls. Furthermore, this study had numerous long-term survivors living for greater than 2 years at the time of recurrence. DNX-2401 was well tolerated with no drug-related Grade 3 or greater adverse events; it demonstrated some ability to pro...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research